Page last updated: 2024-10-24

camostat and Nephrotic Syndrome

camostat has been researched along with Nephrotic Syndrome in 2 studies

camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.

Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Asami, T1
Ohsawa, S1
Tomisawa, S1
Hashimoto, K1
Toyabe, S1
Sakai, K1
Makino, H1
Onbe, T1
Kumagai, I1
Murakami, K1
Ota, Z1

Other Studies

2 other studies available for camostat and Nephrotic Syndrome

ArticleYear
Glomerular deposition of alpha 2-macroglobulin in a child with steroid refractory nephrotic syndrome.
    Nephron, 1992, Volume: 61, Issue:2

    Topics: alpha-Macroglobulins; Child, Preschool; Esters; Gabexate; Guanidines; Humans; Kidney Glomerulus; Mal

1992
A proteinase inhibitor reduces proteinuria in nephrotic syndrome.
    American journal of nephrology, 1991, Volume: 11, Issue:2

    Topics: Esters; Gabexate; Guanidines; Humans; Nephrotic Syndrome; Protease Inhibitors; Proteinuria

1991